Mais la polymyxine n'est pas du tout absorbée dans le sang du système gastro-intestinal et n'a d'effet que dans l'intestin et est utile pour le traitement des infections intestinales metronidazole prix Internet en y faisant des achats permettant d’économiser jusqu'à soixante-dix pour cent, tout en étant sûr de la qualité des produits pharmaceutiques.
Healing of Neuropathic Foot Ulcer using a Novel ‘Wound Boot’ (Kerraboot™)
Leigh R1, Latif N1, Hollingsworth S2, Barker S2, Hurel SJ1
INITIAL MANAGEMENT OF PATIENT'S HEEL ULCERS
Department of Diabetes1 and Surgery2, University College Hospitals, London,
IV antibiotics (ceftazidime, flucloxacillin, ciprofloxacin, metronidazole)
Wound care (dry dressings changed every 2 days)
A 67-year-old man, with poorly controlled Type 2 diabetes, developed
ulceration of both heels during a prolonged hospital admission for septicaemia.
The left heel ulcer measured 8cm in maximum diameter and was approximately 1 cm deep (Figure 1). The right heel ulcer measured 3cm in maximum diameter
and was approximately 0.3cm in depth. He had a peripheral sensory neuropathy.
Doppler arterial ultrasound gave abnormally high ankle-brachial pressure indices,
secondary to vessel calcification. Plain radiographs of the foot were suggestive of
underlying osteomyelitis of the calcaneum. Magnetic resonance and nuclearimaging supported this diagnosis.
Despite bed rest, wound toileting and appropriate antimicrobials, the left heel
ulcer continued to deteriorate with ulceration and infection spreading proximally
to involve the posterior tibial compartment. To circumvent amputation,
considered at the time to be the only suitable procedure, a novel ‘wound boot
was employed. The boot has been designed to provide a highly cost-effective,
carer-friendly alternative to traditional dressings, whilst providing an optimal
environment for wound healing. The boot was changed twice daily, often by the
patient himself, and used in total for three weeks. Over this period, the infectionresolved completely and the wound showed dramatic signs of healing (Figure 2).
Diabetic neuropathic ulceration is extremely difficult to treat. Ischaemia andinfection, affecting superficial tissues or the underlying bone, frequentlycomplicate the condition. The management of these chronic ulcers ismultidisciplinary; requiring scrupulous wound hygiene, careful choice and regular
MANAGEMENT OF LEFT HEEL ULCER WITH KERRABOOT
changing of dressings, systemic antibiotic therapy, and limb rest. Despite intensivemanagement, healing time is frequently protracted and success rates are poor. The
was applied twice daily for 24 days.
management of chronic diabetic foot ulcers makes considerable demands on
The patient was easily able to change the boot, after simple instruction.
nursing time, in hospitals and the community. [It has been estimated that over
25% of the district nurse’s workload involves ulcer care.]
‘wound boot’ (Ark Therapeutics) is a tri-laminar, foot-shaped
plastic boot, which fastens securely around the leg to enclose the area of
ulceration. The key elements of the Kerraboot
• Warm, moist, protected environment – to promote wound granulation and
ulcer margins contract and granulation at base of ulcer; CRP 12.7
• Super-absorbent padding – to remove excess moisture and wound exudate,
• Integral; charcoal filter and carbon impregnated material – to eliminate odour.
• Textured base – to prevent slipping during patient mobilisation.
• Patient – male, 67 years.
– with weekly review at diabetes podiatry clinic.
Antibiotics – rifampicin and fusidic acid.
• 1983 Type 2 diabetes – glibenclamide (10 mg o.d.)
• Poor glycaemic control – glycosylated haemoglobin 12.5% (normal 4-6%)
• Regular alcohol consumption – 6 units daily
POTENTIAL BENEFITS OF THE KERRABOOT FOR DIABETIC FOOT ULCERS
• 1987 progressive neuropathy – initially left foot, then both feet
• Other diabetic complications – proliferative retinopathy and nephropathy
• Warm, moist, protected environment to promote wound healing
• 1996 CVA – persistent left hemi-paresis
• Super-absorbent material to absorb exudate and excessive moisture
• June 1999 – Gram-negative septicaemia (secondary to UTI) - prolonged
• Transparent material to allow easy monitoring of the ulcer
• Efficient odour control to improve patient and ward acceptability
• Development of pressure sores to heels
– discharged, ulcer care by
• Ease of use – patient or carer can change Kerraboot with minimum of
• October 1999 significant deterioration of both ulcers – re-admitted to
• Potential cost benefits from reduced hospitalisation and nursing workload
• Opportunity to increase patient involvement in wound management.
Both ulcers produced a brown, foul-smelling exudate. The right ulcer was 3cm in
diameter and 0.3cm deep; it showed no sign of cellulitis. The left ulcer measured
approximately 8cm in diameter and was 1cm deep. The surrounding tissue wasvery macerated and there was local cellulitis.
This intervention appeared to promote healing of a chronic, infected,necrotic, neuropathic heel ulcer in a diabetic patient, and circumvented the
Doppler arterial ultrasound – high ankle-brachial pressure indices (e.g. Dorsalis
pedis: L >300mmHg, R 240mmHg), probably secondary to vessel calcification.
The evidence from this case suggests that the Kerraboot produces an
Microbiology – initial wound cultures grew Pseudomonas aeruginosa
environment conducive to wound healing. A study is currently underway to
Radiography, MR and nuclear imaging – osteomyelitis of calcaneum.
Biochemistry – C-reactive protein (CRP) 94, erythrocyte sedimentation rate (ESR)80, white cell count (WCC) 8.3 x 109/L.
S u p p o r t e d by a n e d u c a t i o n a l g ra n t f ro m A r t Th e ra p e u t i c s
6 Wa r re n M ew s , L o n d o n W 1 T 6 A R Te l e p h o n e . 0 2 0 7 3 8 8 7 7 2 2
REPRINT FROM JULY 28, 2008 BioCentury Roche’s opportunity Most analyses of Roche’s offer to buy the rest of Whether or not Genentech management thinks the initial Genentech Inc. have focused on whether the price is too offer insulting, they’re big boys and girls and can take it. Theylow, or Genentech Chairman and CEO Arthur Levinson wasknow — as does anyone who has done a
BASE 8 is a kit manufactured by Optima Ovest to specifically allow pharmacists to easily prepare suspensions of Omeprazole and Lansoprazole. BASE 8 is a pleasant tasting, sweetened, raspberry and marshmallow flavoured suspending base which contains only 7.3mg/mL of Na+ compared with Sodium Bicarbonate 8.4% solution which contains 23mg/mL of Na+. The excellent taste of BASE 8 will increase the